Jafron Biomedical Co (SZSE:300529) Cash And Cash Equivalents : ¥2,392 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Jafron Biomedical Co Cash And Cash Equivalents?

Jafron Biomedical Co's quarterly cash and cash equivalents increased from Sep. 2023 (¥2,703.54 Mil) to Dec. 2023 (¥2,810.29 Mil) but then stayed the same from Dec. 2023 (¥2,810.29 Mil) to Mar. 2024 (¥2,392.25 Mil).

Jafron Biomedical Co's annual cash and cash equivalents increased from Dec. 2021 (¥2,319.45 Mil) to Dec. 2022 (¥2,558.76 Mil) and increased from Dec. 2022 (¥2,558.76 Mil) to Dec. 2023 (¥2,810.29 Mil).

Jafron Biomedical Co Cash And Cash Equivalents Historical Data

The historical data trend for Jafron Biomedical Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jafron Biomedical Co Cash And Cash Equivalents Chart

Jafron Biomedical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

1,271.73

1,575.05

2,319.45

2,558.76

2,810.29

Jafron Biomedical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															3,084.03	2,847.02	2,703.54	2,810.29	2,392.25

Jafron Biomedical Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Jafron Biomedical Co (SZSE:300529) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Jafron Biomedical Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Jafron Biomedical Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Jafron Biomedical Co (SZSE:300529) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jafron Biomedical Co Ltd (SZSE:300529) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 98, Science and Technology 6th Road, High-tech Zone, Guangdong Province, Zhuhai, CHN, 519085

Website

http://www.jafron.com

Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.

Executives

Li Feng	Director
He Xiao Lian	Executives
Dong Fan	Directors, Directors, and Executives
Ceng Kai	Directors, executives
Tang Xian Min	Directors, executives
Zhang Ming Yuan	Secretary Dong
Fang Li Hua	Supervisors
Zhang Guang Hai	Directors, executives
Li De Zhi	Executives
Lu Shao Zhang	Executives

Jafron Biomedical Co (SZSE:300529) Headlines

No Headlines